个人简历

1979 美国耶鲁大学医学院博士后。
1976 英国利物浦大学博士研究生。
1973 英国利物浦大学本科。

研究领域

乳腺癌：（1）乳腺癌的分子机理；（2）催乳素及催乳素受体在乳腺癌形成、发展及预后中的作用；（3）乳腺癌的治疗（药物设计）。
免疫学：乳汁中免疫细胞对后代胸腺发育之影响。

近期论文

YangNY, Lopez-Bergami P, Goydos JS, Yip D,WalkerAM, Pasquale EB,Ethell IM. The EphB4 receptor promotes the growth of melanoma cells expressingthe ephrin-B2 ligand. Pigment Cell Melanoma Res. 2010 Oct;23(5):684-7.
Terasaki Y, Yahiro K,Pacheco-Rodriguez G, Steagall WK, Stylianou MP, Evans JF, Walker AM, Moss J.Effects of prolactin on TSC2-null Eker rat cells and in pulmonarylymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010 Aug 15;182(4):531-9.
Tan D, Walker AM. Short form1b human prolactin receptor down-regulates expression of the long form. J MolEndocrinol. 2010 Mar;44(3):187-94.
Huang KT, Walker AM. Long termincreased expression of the short form 1b prolactin receptor in PC-3 humanprostate cancer cells decreases cell growth and migration, and causes multiplechanges in gene expression consistent with reduced invasive capacity. Prostate.2010 Jan 1;70(1):37-47.
Ueda EK, Soares CR, BartoliniP, DeGuzman A, Lorenson MY,WalkerAM. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted byeukaryotic cells has a conformation with an increased positive surface chargecompared to that of unmodified prolactin. Biochemistry. 2009 Jul28;48(29):6887-97. Erratum in: Biochemistry. 2009 Sep 15;48(36):8764.
Chen Y, Huang K, Chen KE,WalkerAM. Prolactin andestradiol utilize distinct mechanisms to increase serine-118 phosphorylationand decrease levels of estrogen receptor alpha in T47D breast cancer cells.Breast Cancer Res Treat. 2010 Apr;120(2):369-77.
HelenaCV, McKee DT, Bertram R,WalkerAM, Freeman ME. The rhythmic secretion of mating-induced prolactin secretion iscontrolled by prolactin acting centrally. Endocrinology. 2009Jul;150(7):3245-51.
Deng C, Ueda E, Chen KE, BulaC,NormanAW,Luben RA, Walker AM. Prolactin blocks nuclear translocation of VDR byregulating its interaction with BRCA1 inosteosarcoma cells. Mol Endocrinol. 2009 Feb;23(2):226-36.
Ma LJ, Walter B, Deguzman A,Muller HK, Walker AM. Trans-epithelial immune cell transfer during sucklingmodulates delayed-type hypersensitivity in recipients as a function of gender.PLoS One. 2008;3(10):e3562.
Huang K, Ueda E, Chen Y,Walker AM. Paradigm-shifters: phosphorylated prolactin and short prolactinreceptors. J Mammary Gland Biol Neoplasia. 2008. Mar;13(1):69-79.
Tan D, Huang KT, Ueda E,WalkerAM. S2 deletionvariants of human PRL receptors demonstrate that extracellular domainconformation can alter conformation of the intracellular signaling domain.Biochemistry. 2008 Jan 8;47(1):479-89. Epub 2007 Dec 15.
Guzmán EA, Langowski JL, DeGuzman A, Muller HK, Walker AM, Owen LB. S179D prolactin diminishes the effectsof UV light on epidermal gamma delta T cells. Mol Cell Endocrinol. 2008 Jan2;280(1-2):6-12.
Williams VL, DeGuzman A, DangH, Kawaminami M, Ho TW, Carter DG, Walker AM. Common and specific effects ofthe two major forms of prolactin in the rat testis. Am J Physiol EndocrinolMetab. 2007 Dec;293(6):E1795-803.
Wang Y, Chiu CT, Nakamura T,Walker AM, Petridou B, Trousdale MD, Hamm-Alvarez SF, Mircheff AK, SchechterJE. Traffic of endogenous, transduced, and endocytosed prolactin in rabbitlacrimal acinar cells. Exp Eye Res. 2007 Dec;85(6):749-61.
Wu W, Zanello L,WalkerAM. S179Dprolactin sensitizes human prostate cancer cells such that physiological concentrationsof 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death.Prostate. 2007 Oct 1;67(14):1498-506.
WalkerAM. S179D prolactin:antagonistic agony! Mol Cell Endocrinol. 2007 Sep 30;276(1-2):1-9.
Ma LJ, Guzmán EA, DeGuzman A,Muller HK,WalkerAM, Owen LB. Local cytokine levels associated with delayed-typehypersensitivity responses: modulation by gender, ovariectomy, and estrogenreplacement. J Endocrinol. 2007. May;193(2):291-7.
Wang Y, Chiu CT, Nakamura T,Walker AM, Petridou B, Trousdale MD, Hamm-Alvarez SF, Schechter JE, MircheffAK. Elevated prolactin redirects secretory vesicle traffic in rabbit lacrimalacinar cells. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1122-34.
WalkerAM. Therapeuticpotential of S179D prolactin--from prostate cancer to angioproliferativedisorders: the first selective prolactin receptor modulator. Expert OpinInvestig Drugs. 2006 Oct;15(10):1257-67.